Does the presence of hepatitis virus B and C influence the evolution of diffuse large B-cell lymphoma?. Issue 6 (June 2015)

• Record Type: Journal Article
• Authors: Rubio, Judit; Franco, Fernando; Sánchez, Antonio; Cantos, Blanca; Méndez, Miriam; Calvo, Virginia; Maximiano, Constanza; Perez, David; Millán, Isabel; Sánchez-Beato, Margarita; Provencio, Mariano
• Is Part Of: Leukemia & lymphoma. Volume 56:Issue 6(2015:Jun.)
• Page Start: 1686
• Page End: 1690
• Publication Date: 2015-06
• Subjects: Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2014.963576
• Languages: English
• ISSNs: 1042-8194

Abstract

<abstract> <title>Abstract</title> <p>Hepatitis infection has a high prevalence in patients with non-Hodgkin lymphoma. Our objective was to evaluate clinical characteristics and survival of patients diagnosed with diffuse large B-cell lymphoma (DLBCL) who were hepatitis B and/or C (HBV/HCV) positive. We reviewed 224 patents diagnosed with DLBCL and found 21 to be HBV/HCV positive (9.3%). Significant differences were found in the number of nodal regions affected, four in HBV/HCV positive versus two in virus negative patients, and in liver involvement, which was greater in HBV/HCV positive patients (28.6% vs. 10%, <italic>p</italic> = 0.028). No significant differences were found in the two groups with respect to the number of relapses or the probability of overall or progression-free survival. Despite the finding of differences with respect to stage, total number of nodal regions affected and liver involvement, HBV/HCV positive and negative patients with DLBCL should receive the same treatment, and the disease responds and evolves equally.</p> </abstract>